Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
Downloads
Introduction: Non-small cell lung cancer (NSCLC) was the primary cause of death in lung cancer. Tyrosine kinase inhibitors (TKIs) were one of the management options for NSCLC. Meanwhile, serum carcinoembryonic antigen (CEA) plays a crucial role in the diagnosis and prognosis of NSCLC patients. This study aimed to determine the effectiveness of epidermal growth factor receptor (EGFR)-TKI based on progression-free survival (PFS) and overall survival (OS) in NSCLC patients with common EGFR mutations.
Methods: This retrospective cohort study used a total sampling method. The serum CEA level was measured before the initial treatment. Tyrosine kinase inhibitors therapy was monitored with PFS and OS. Statistical analysis for comparing prognosis in NSCLC among TKI groups used Kruskal-Wallis, analysis of variance (ANOVA), Mann-Whitney, and Spearman’s rho tests. A significant analysis referred to a p-value of <0.05.
Results: The participants were 189 patients, consisting of 106 on gefitinib, 43 on erlotinib, and 40 on afatinib. The average PFS values in the gefitinib, erlotinib, and afatinib groups were 9.9±5.25, 8.77±4.53, and 12.83±7.02 months, respectively (p=0.016). Furthermore, there were no significant OS among the gefitinib (14.91±7.61 months), erlotinib (14.54±7.64 months), and afatinib group (15.51±8.13 months, p=0.867). There was a significant correlation between CEA levels and PFS (r=0.146; p=0.046) and between CEA levels and OS (r=0.223; p=0.004).
Conclusion: Although afatinib may prolong PFS compared with gefitinib and erlotinib, it did not significantly impact OS. Increased serum CEA levels before treatment significantly improved PFS and OS. However, elevated CEA levels are usually associated with a poor prognosis in NSCLC.
Alduais Y, Zhang H, Fan F, et al. Non-Small Cell Lung Cancer (NSCLC): A Review of Risk Factors, Diagnosis, and Treatment. Medicine 2023; 102: e32899. [PubMed]
Hanafi AR, Hanif MA, Pangaribuan MTG, et al. Genomic Features of Lung Cancer Patients in Indonesia’s National Cancer Center. BMC Pulm Med 2024; 24: 43. [PubMed]
Asmara OD, Tenda ED, Singh G, et al. Lung Cancer in Indonesia. J Thor Oncol 2023; 18: 1134–1145. [PubMed]
Wulandari L, Soegiarto G, Febriani A, et al. Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients. Indian J Surg Oncol 2021; 12: 65–71. [PubMed]
Peng Z, Lin H, Zhou K, et al. Predictive Value of Pretreatment PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis. World J Surg Oncol 2021; 19: 145. [PubMed]
Zhang M, Zhu L, Liang S, et al. Pulmonary Function Test-Related Prognostic Models in Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemoimmunotherapy. Front Oncol 2024; 14: 1411436. [PubMed]
Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem 2020; 20: 815–834. [PubMed]
Heriyanto DS, Trisnawati I, Kumara EG, et al. The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. Pulm Med 2020; 2020: 3578748. [PubMed]
Miura S, Koh Y, Azuma K, et al. Afatinib Plus Osimertinib in the Treatment of Osimertinib-Resistant Non-Small Cell Lung Carcinoma: A Phase I Clinical Trial. BMC Cancer 2023; 23: 6. [PubMed]
Arrieta O, Varela-Santoyo E, Cardona AF, et al. Association of Carcinoembryonic Antigen Reduction with Progression-Free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer 2021; 22: 510–522. [PubMed]
Liu M, Zhou Z, Liu F, et al. CT and CEA-Based Machine Learning Model for Predicting Malignant Pulmonary Nodules. Cancer Sci 2022; 113: 4363–4373. [PubMed]
Xie H, Wei L, Wang Q, et al. Grading Carcinoembryonic Antigen Levels Can Enhance the Effectiveness of Prognostic Stratification in Patients with Colorectal Cancer: A Single-Centre Retrospective Study. BMJ Open 2024; 14: e084219. [PubMed]
Merinda V, Soegiarto G, Wulandari L. T790M Mutations Identified by Circulating Tumor DNA Test in Lung Adenocarcinoma Patients who Progressed on First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Lung India 2020; 37: 13–18. [PubMed]
Galvez-Nino M, Ruiz R, Pinto JA, et al. Lung Cancer in the Young. Lung 2020; 198: 195–200. [PubMed]
Ganti AK, Klein AB, Cotarla I, et al. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients with Non-Small Cell Lung Cancer in the US. JAMA Oncol 2021; 7: 1824–1832. [PubMed]
Melosky B, Kambartel K, Häntschel M, et al. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Mol Diagn Ther 2022; 26: 7–18. [PubMed]
Soo RA, Reungwetwattana T, Perroud HA, et al. Prevalence of EGFR Mutations in Patients with Resected Stages I to III NSCLC: Results from the EARLY-EGFR Study. J Thorac Oncol 2024; 19: 1449–1459. [PubMed]
Helal AA, Kamal IH, Osman A, et al. The Prevalence and Clinical Significance of EGFR Mutations in Non-Small Cell Lung Cancer Patients in Egypt: A Screening Study. J Egypt Natl Canc Inst 2024; 36: 39. [PubMed]
Frost MG, Jensen KJ, Jimenez-Solem E, et al. Sex Disparities in Advanced Non-Small Cell Lung Cancer Survival: A Danish Nationwide Study. Lung Cancer 2025; 202: 108485. [ScienceDirect]
Abbas M, Kassim SA, Habib M, et al. Clinical Evaluation of Serum Tumor Markers in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Palliative Chemotherapy in China. Front Oncol 2020; 10: 800. [PubMed]
Shiels MS, Graubard BI, McNeel TS, et al. Trends in Smoking-Attributable and Smoking-Unrelated Lung Cancer Death Rates in the United States, 1991-2018. J Natl Cancer Inst 2024; 116: 711–716. [PubMed]
Zhu J, Branstetter S, Lazarus P, et al. Smoking, Lung Cancer Stage, and Prognostic Factors-Findings from the National Lung Screening Trial. Int J Environ Res Public Health; 21. Epub ahead of print March 2024. [PubMed]
Zhang H, He M, Wan R, et al. Establishment and Evaluation of EGFR Mutation Prediction Model based on Tumor Markers and CT Features in NSCLC. J Healthc Eng 2022; 2022: 8089750. [PubMed]
Gan T, An W, Long Y, et al. Correlation between Carcinoembryonic Antigen (CEA) Expression and EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis. Clin Transl Oncol 2024; 26: 991–1000. [PubMed]
Jiao Z, Cao S, Li J, et al. Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome. Front Mol Biosci 2021; 8: 686313.
Lee J, Lee DH, Park JE, et al. Clinical Impact of Pleural Fluid Carcinoembryonic Antigen on Therapeutic Strategy and Efficacy in Lung Adenocarcinoma Patients with Malignant Pleural Effusion. Korean J Intern Med 2024; 39: 318–326. [PubMed]
van den Heuvel M, Holdenrieder S, Schuurbiers M, et al. Serum Tumor Markers for Response Prediction and Monitoring of Advanced Lung Cancer: A Review Focusing on Immunotherapy and Targeted Therapies. Tumour Biol 2024; 46: S233–S268. [PubMed]
Tang FH, Wong HYT, Tsang PSW, et al. Recent Advancements in Lung Cancer Research: A Narrative Review. Transl Lung Cancer Res 2025; 14: 975–990. [PubMed]
Zappa C, Mousa SA. Non-Small Cell Lung Cancer: Current Treatment and Future Advances. Transl Lung Cancer Res 2016; 5: 288–300. [PubMed]
Megyesfalvi Z, Gay CM, Popper H, et al. Clinical Insights into Small Cell Lung Cancer: Tumor Heterogeneity, Diagnosis, Therapy, and Future Directions. CA Cancer J Clin 2023; 73: 620–652. [PubMed]
Strum S, Vincent M, Gipson M, et al. Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-Small Cell Lung Cancer Management. Oncotarget 2024; 15: 381–388. [PubMed]
Copyright (c) 2025 Agus Andreas Santoso, Suryanti Dwi Pratiwi, Yani Jane Sugiri, Harun Al Rasyid, Aditya Sri Listyoko

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.